| scholarly article | Q13442814 |
| P50 | author | Alberto Bardelli | Q28321691 |
| Monica Rodolfo | Q37376562 | ||
| Aldo Scarpa | Q37392347 | ||
| P2093 | author name string | Antonio Marchetti | |
| Fiamma Buttitta | |||
| Francesca Molinari | |||
| Lara Felicioni | |||
| Milo Frattini | |||
| Sara Malatesta | |||
| Fonnet E Bleeker | |||
| W Peter Vandertop | |||
| Margaret Knowles | |||
| Dirk Troost | |||
| Sieger Leenstra | |||
| Simona Lamba | |||
| Aniello Cerrato | |||
| Theo Hulsebos | |||
| P2860 | cites work | The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase | Q22010653 |
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| The consensus coding sequences of human breast and colorectal cancers | Q27861035 | ||
| The genomic landscapes of human breast and colorectal cancers | Q27861078 | ||
| Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity | Q28116883 | ||
| Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells | Q28589157 | ||
| Genetic pathways to primary and secondary glioblastoma | Q35757144 | ||
| DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin | Q38509007 | ||
| Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma | Q40144627 | ||
| Genetic pathways to glioblastoma: a population-based study | Q44673208 | ||
| AKT1(E17K) in human solid tumours | Q46574533 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 7-11 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Human Mutation | Q5937269 |
| P1476 | title | IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors | |
| P478 | volume | 30 |
| Q95841103 | "Mitochondrial Toolbox" - A Review of Online Resources to Explore Mitochondrial Genomics |
| Q43109642 | 2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas |
| Q57799080 | A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an Mutation |
| Q34239738 | A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples |
| Q64116075 | A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma |
| Q39200135 | A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment |
| Q36446183 | A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. |
| Q38712122 | A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors |
| Q37456898 | A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation |
| Q34635517 | A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. |
| Q36449844 | A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. |
| Q48446221 | ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma |
| Q30439629 | Absence of AKT1 mutations in glioblastoma |
| Q34607312 | Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas |
| Q42091501 | Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers |
| Q33782633 | Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features |
| Q38014949 | Advances in malignant glioma drug discovery |
| Q36608747 | Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention |
| Q47131592 | An expression screen for aged-dependent microRNAs identifies miR-30a as a key regulator of aging features in human epidermis |
| Q47356155 | Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation |
| Q37015509 | Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial |
| Q38997694 | Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors |
| Q36544617 | BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. |
| Q58766030 | Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas |
| Q42871997 | COLD PCR HRM: a highly sensitive detection method for IDH1 mutations |
| Q33965980 | Cancer genomics identifies determinants of tumor biology |
| Q37802750 | Cancer-associated IDH mutations: biomarker and therapeutic opportunities |
| Q24320239 | Cancer-associated IDH1 mutations produce 2-hydroxyglutarate |
| Q35705274 | Cancer-associated isocitrate dehydrogenase mutations |
| Q38757601 | Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability |
| Q42141882 | Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations |
| Q37390701 | Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations |
| Q46054736 | Cancer. Puzzling patterns of predisposition |
| Q64120431 | Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production |
| Q39068086 | Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients |
| Q48579074 | Clinicopathological features of human brainstem gliomas |
| Q36109794 | Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event |
| Q36866028 | Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. |
| Q55409347 | Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report. |
| Q34588501 | Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma |
| Q33975580 | Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. |
| Q38410050 | Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry |
| Q41525199 | Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies |
| Q28246788 | Determination of phosphate-activated glutaminase activity and its kinetics in mouse tissues using metabolic mapping (quantitative enzyme histochemistry) |
| Q43656999 | Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants |
| Q35441165 | Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma |
| Q42042456 | Distribution bias analysis of germline and somatic single-nucleotide variations that impact protein functional site and neighboring amino acids |
| Q38639828 | Driver mutations of cancer epigenomes. |
| Q36558431 | Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma |
| Q51327505 | Emerging drugs for biliary cancer. |
| Q28395302 | Epidemiologic and molecular prognostic review of glioblastoma |
| Q35705307 | Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping |
| Q90025515 | Friend or foe-IDH1 mutations in glioma 10 years on |
| Q64073085 | Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma |
| Q34647741 | Gene mutations and molecularly targeted therapies in acute myeloid leukemia. |
| Q45946934 | Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients. |
| Q60054025 | Genetics of Glioblastoma in Moroccan population: Review of literature |
| Q34735661 | Glial progenitors as targets for transformation in glioma |
| Q36225372 | Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). |
| Q38411964 | Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. |
| Q29619709 | Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha |
| Q38747962 | HOT mutation screening in human glioblastomas |
| Q55463524 | High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. |
| Q36737930 | Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas |
| Q46244463 | IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients |
| Q55462570 | IDH mutation status in prostate cancer. |
| Q37778541 | IDH mutations in glioma and acute myeloid leukemia |
| Q38022856 | IDH mutations in human glioma |
| Q33615867 | IDH mutations: genotype-phenotype correlation and prognostic impact. |
| Q55457146 | IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. |
| Q41721821 | IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours |
| Q39568860 | IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo |
| Q33709922 | IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway |
| Q33897586 | IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study |
| Q41137508 | IDH1 and IDH2 hotspot mutations are not found in canine glioma. |
| Q43089505 | IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. |
| Q34562170 | IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. |
| Q42858887 | IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders |
| Q24561928 | IDH1 and IDH2 mutations in gliomas |
| Q38052534 | IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives |
| Q54584786 | IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. |
| Q39506081 | IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? |
| Q58738690 | IDH1 is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment |
| Q34458930 | IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group |
| Q42164790 | IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas |
| Q34603959 | IDH1 mutations in a Brazilian series of Glioblastoma. |
| Q48404919 | IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. |
| Q37875253 | IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature |
| Q34330224 | IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain |
| Q38227739 | IDH1/2 mutation detection in gliomas |
| Q33597773 | IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients |
| Q27851701 | IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma |
| Q58023817 | IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis |
| Q24300323 | Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer |
| Q24612429 | Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma |
| Q38755638 | Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. |
| Q39458545 | Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production |
| Q34069325 | Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. |
| Q55462991 | Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. |
| Q41756350 | Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas |
| Q47853442 | In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas |
| Q37837594 | Inborn and acquired metabolic defects in cancer |
| Q37485784 | Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. |
| Q45927900 | Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. |
| Q36157713 | Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas |
| Q37226526 | Is glioblastoma an epigenetic malignancy? |
| Q33699608 | Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate |
| Q36213070 | Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype |
| Q36925070 | Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas |
| Q33965102 | Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism |
| Q54981076 | Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability. |
| Q54393106 | Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. |
| Q38098586 | Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review |
| Q36367409 | Isocitrate dehydrogenase mutations in gliomas |
| Q34224704 | Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target |
| Q37835774 | Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas |
| Q27001014 | Isocitrate dehydrogenase mutations: new opportunities for translational research |
| Q33628344 | Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? |
| Q41247181 | Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight |
| Q57184032 | It's complicated… mA-dependent regulation of gene expression in cancer |
| Q35581456 | LOX expression and functional analysis in astrocytomas and impact of IDH1 mutation |
| Q37410615 | MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. |
| Q36299659 | Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas |
| Q64245167 | Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications |
| Q38151521 | Metabolic alteration in tumorigenesis |
| Q38083800 | Metabolic modulation of epigenetics in gliomas |
| Q37903736 | Metabolism and brain cancer |
| Q58617984 | Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma |
| Q60930189 | Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis |
| Q35873466 | Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients |
| Q27851561 | Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study |
| Q27001295 | Molecular biology of gliomas: present and future challenges |
| Q37780495 | Molecular diagnostics of gliomas: state of the art. |
| Q27665370 | Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H |
| Q46719423 | Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency |
| Q47738114 | Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data |
| Q34755642 | Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation |
| Q39299157 | Mutant IDH1 is required for IDH1 mutated tumor cell growth. |
| Q40370855 | Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis |
| Q64974414 | Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. |
| Q37649243 | Mutant metabolic enzymes are at the origin of gliomas |
| Q34807321 | Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival |
| Q55463689 | Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. |
| Q37313504 | Mutational profile of GNAQQ209 in human tumors. |
| Q21261249 | Mutational profiling of kinases in glioblastoma |
| Q46059225 | Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer |
| Q39695872 | Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas |
| Q38847239 | Myocyte enhancer factor 2D promotes tumorigenicity in malignant glioma cells |
| Q39167472 | New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. |
| Q38658533 | Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria |
| Q34053028 | Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy |
| Q35990061 | Novel Biomarker Proteins in Chronic Lymphocytic Leukemia: Impact on Diagnosis, Prognosis and Treatment |
| Q27687464 | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 |
| Q27005930 | Novel therapeutic targets of tumor metabolism |
| Q36501683 | Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice |
| Q37399898 | Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer |
| Q37564201 | Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy |
| Q82467819 | Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate |
| Q90275490 | Pediatric low-grade glioma in the era of molecular diagnostics |
| Q47235352 | Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins |
| Q37791112 | Practical molecular diagnostics in neuropathology: making a tough job a little easier |
| Q48309717 | Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status |
| Q37873473 | Predictive and prognostic factors for gliomas |
| Q37078999 | Prioritization schema for immunotherapy clinical trials in glioblastoma |
| Q37750781 | Prognostic markers in gliomas |
| Q40784811 | Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin |
| Q43013129 | Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients |
| Q49504968 | R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes |
| Q36705913 | Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients. |
| Q93049221 | Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms |
| Q35142605 | Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing |
| Q24632928 | Recent advances in the molecular understanding of glioblastoma |
| Q24634204 | Recurring mutations found by sequencing an acute myeloid leukemia genome |
| Q28303890 | Regulation of cancer cell metabolism |
| Q46082218 | Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma |
| Q42739226 | Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors |
| Q55462450 | Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. |
| Q43411833 | Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. |
| Q43238974 | Something old and something new about molecular diagnostics in gliomas |
| Q38260977 | Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. |
| Q89975399 | Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening |
| Q53607552 | Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1. |
| Q36668364 | TET family proteins: oxidation activity, interacting molecules, and functions in diseases |
| Q26744441 | Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives |
| Q34064643 | The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival |
| Q54637633 | The Nature and Timing of Specific Copy Number Changes in the Course of Molecular Progression in Diffuse Gliomas: Further Elucidation of Their Genetic “Life Story” |
| Q37443338 | The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. |
| Q34061985 | The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. |
| Q27851550 | The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma |
| Q24604760 | Understanding the Warburg effect: the metabolic requirements of cell proliferation |
| Q30452178 | Update on molecular findings, management and outcome in low-grade gliomas |
| Q90042086 | Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells |
| Q36832167 | What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer |
| Q36788229 | What do we know about IDH1/2 mutations so far, and how do we use it? |
Search more.